Initiation rates for ADM GLP-1 RA are about the same in June 2025, relative to March 2025 (+1.1%)
Tyramine does not cross the blood-brain-barrier (Bertler et al, 1966
1991 (landmark Italian trial): A double-blind, placebo-controlled trial involving 130 patients with Alzheimer's disease demonstrated that one year of ALCAR treatment resulted in a slower rate of deterioration compared to placebo across 13 of 14 outcome measures, including significant improvements in the Blessed Dementia Scale, logical intelligence, verbal critical abilities, long-term verbal memory, and selective attention [5][17]
DeGiorgio CM, Hertling D, Curtis A, Murray D, Markovic D
Think of it as hitting a rejuvenation button bringing unmatched vitality back to your body
Side effect comparison: Nausea: Tirzepatide rates range from 12% to 33% depending on dose, comparable to cagrilintide Vomiting: Tirzepatide higher than cagrilintide Diarrhea: Similar rates Injection site reactions: Cagrilintide significantly higher than tirzepatide Fatigue: Tirzepatide fatigue is commonly reported, comparable to cagrilintide Some researchers are exploring cagrilintide combined with tirzepatide for potentially enhanced effects